Country: Canada
Language: English
Source: Health Canada
ANASTROZOLE
TEVA CANADA LIMITED
L02BG03
ANASTROZOLE
1MG
TABLET
ANASTROZOLE 1MG
ORAL
30
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0128681001; AHFS:
APPROVED
2014-12-01
TEVA-ANASTROZOLE Page 1 of 68 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-ANASTROZOLE Anastrozole Tablets Tablet, 1 mg, Oral Teva Standard Non-Steroidal Aromatase Inhibitor (L02BG03) Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 Canada www.tevacanada.com Date of Initial Authorization: October 25, 2012 Date of Revision: March 16, 2023 Submission Control Number: 271296 TEVA-ANASTROZOLE Page 2 of 68 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Musculoskeletal 03/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION………………………………………………………………………5 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment .......................................................... 5 4.4 Administration ............................................................................................................ 5 4.5 Missed Dose .............................................................. Read the complete document